Ascelia Pharma AB (OSTO:ACE) Revenue: kr0.00 Mil (TTM As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
28 GF Score
Price kr0.66
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Revenue?

Ascelia Pharma AB OSTO:ACE -1.48% 28 Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil. Ascelia Pharma AB's Revenue per Share for the three months ended in Mar. 2026 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Ascelia Pharma AB  (OSTO:ACE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ascelia Pharma AB Revenue Related Terms


Ascelia Pharma AB Revenue Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Revenue Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSTO:ACE vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Revenue distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Revenue falls into.


OSTO:ACE
28GF Score
Ascelia Pharma AB OSTO:ACE
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of kr0.00 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Revenue of kr0.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Revenue too high?
Ascelia Pharma AB's current Revenue is kr0.00 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Revenue compare to VRTX and REGN?
Ascelia Pharma AB's Revenue of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Revenue of kr0.00 Mil. The current Revenue is kr0.00 Mil. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score

Get the complete analysis for OSTO:ACE

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.66
Price